We only succeed when employers and their employees do, too. To mark the announcement of these new products, which will be available in January, Noom also published a whitepaper today Breaking the GLP-1 Cost Cycle: Transforming Access, Cutting Costs, and Shaping the Future of Obesity Care
When a clinic sells oral compounded peptide tablets alongside injections without explaining the differences, patients are left to make medical decisions without proper context
There is no mechanistic or clinical rationale for taking breaks
Zhang A, Wang Y, Sui X, Xie T, Zhang J, Huang Y, et al
GLP-1s are easy to get off